Increased Varenicline Dosing
Phase 2Small molecule
Increased Varenicline Dosing is one of 36 small molecule programs targeting Chronic Pancreatitis. It is currently in Phase 2.
2
Indications
1
Total Trials
0
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
51 competitors in Chronic Pancreatitis
#DrugCompanyPhaseTrials
1Creon
AbbVieApproved
Glucophage
EMD SeronoApproved
Marcaine
IInnocoll
Approved
VIOKACE
DDigestive Care, Inc.
Phase 3
Kenalog
BBassett Healthcare
Phase 3
Actos
TakedaPhase 2
Thalomid
Bristol-Myers SquibbPhase 2
Actemra
RochePhase 2
Zocor
OOrganon and Co
Phase 2
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMayo Clinic